{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:44:46Z","timestamp":1790203486247,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2006,5,11]],"date-time":"2006-05-11T00:00:00Z","timestamp":1147305600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s10495-006-8048-9","type":"journal-article","created":{"date-parts":[[2006,5,14]],"date-time":"2006-05-14T16:08:29Z","timestamp":1147622909000},"page":"1175-1193","source":"Crossref","is-referenced-by-count":71,"title":["The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells"],"prefix":"10.1007","volume":"11","author":[{"given":"Albert F.","family":"Kabore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"McCrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer B.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,5,11]]},"reference":[{"issue":"5","key":"8048_CR1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","volume":"5","author":"J Adams","year":"2004","unstructured":"Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5(5):417\u2013421","journal-title":"Cancer Cell"},{"issue":"4","key":"8048_CR2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.leu.2402417","volume":"16","author":"JB Almond","year":"2002","unstructured":"Almond JB, Cohen GM (2002) The proteasome: A novel target for cancer chemotherapy. Leukemia 16(4):433\u2013443","journal-title":"Leukemia"},{"issue":"17","key":"8048_CR3","first-page":"6316","volume":"9","author":"PM Voorhees","year":"2003","unstructured":"Voorhees PM, Dees EC, O\u2019Neil B, Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9(17):6316\u20136325","journal-title":"Clin Cancer Res"},{"issue":"26","key":"8048_CR4","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et\u00a0al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609\u20132617","journal-title":"N Engl J Med"},{"issue":"8","key":"8048_CR5","first-page":"828","volume":"5","author":"QP Dou","year":"2002","unstructured":"Dou QP, Goldfarb RH (2002) Bortezomib (millennium pharmaceuticals). IDrugs 5(8):828\u2013834","journal-title":"IDrugs"},{"issue":"4","key":"8048_CR6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1034\/j.1600-0609.2000.065004221.x","volume":"65","author":"C Naujokat","year":"2000","unstructured":"Naujokat C, Sezer O, Zinke H, Leclere A, Hauptmann S, Possinger K (2000) Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1(Cip1 in human immature leukemic cells. Eur J Haematol 65(4):221\u2013236","journal-title":"Eur J Haematol"},{"issue":"1","key":"8048_CR7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","volume":"171","author":"LV Pham","year":"2003","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ (2003) Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171(1):88\u201395","journal-title":"J Immunol"},{"issue":"3","key":"8048_CR8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000016308","volume":"9","author":"B Wagenknecht","year":"1999","unstructured":"Wagenknecht B, Hermisson M, Eitel K, Weller M (1999) Proteasome inhibitors induce p53\/p21-independent apoptosis in human glioma cells. Cell Physiol Biochem 9(3):117\u2013125","journal-title":"Cell Physiol Biochem"},{"issue":"21","key":"8048_CR9","first-page":"7338","volume":"63","author":"SA Williams","year":"2003","unstructured":"Williams SA, McConkey DJ (2003) The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 63(21):7338\u20137344","journal-title":"Cancer Res"},{"issue":"2","key":"8048_CR10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.yexcr.2004.02.001","volume":"295","author":"C Yu","year":"2004","unstructured":"Yu C, Rahmani M, Dent P, Grant S (2004) The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 295(2):555\u2013566","journal-title":"Exp Cell Res"},{"issue":"17","key":"8048_CR11","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/sj.onc.1206326","volume":"22","author":"G Dewson","year":"2003","unstructured":"Dewson G, Snowden RT, Almond JB, Dyer MJ, Cohen GM (2003) Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene 22(17):2643\u20132654","journal-title":"Oncogene"},{"issue":"1","key":"8048_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1009604900979","volume":"3","author":"HC Drexler","year":"1998","unstructured":"Drexler HC (1998) Programmed cell death and the proteasome. Apoptosis 3(1):1\u20137","journal-title":"Apoptosis"},{"issue":"36","key":"8048_CR13","doi-asserted-by":"crossref","first-page":"33714","DOI":"10.1074\/jbc.M302559200","volume":"278","author":"YH Ling","year":"2003","unstructured":"Ling YH, Liebes L, Zou Y, Perez-Soler R (2003) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278(36):33714\u201333723. Epub 2003 Jun 23","journal-title":"J Biol Chem"},{"issue":"39","key":"8048_CR14","doi-asserted-by":"crossref","first-page":"36611","DOI":"10.1074\/jbc.M200317200","volume":"277","author":"M MacFarlane","year":"2002","unstructured":"MacFarlane M, Merrison W, Bratton SB, Cohen GM (2002) Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 277(39):36611\u201336616","journal-title":"J Biol Chem"},{"issue":"1","key":"8048_CR15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1523\/JNEUROSCI.20-01-00259.2000","volume":"20","author":"JH Qiu","year":"2000","unstructured":"Qiu JH, Asai A, Chi S, Saito N, Hamada H, Kirino T (2000) Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J Neurosci 20(1):259\u2013265","journal-title":"J Neurosci"},{"issue":"1","key":"8048_CR16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1097-2765(04)00156-X","volume":"14","author":"XM Sun","year":"2004","unstructured":"Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM (2004) Caspase activation inhibits proteasome function during apoptosis. Mol Cell 14(1):81\u201393","journal-title":"Mol Cell"},{"issue":"10","key":"8048_CR17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1349-7006.2004.tb02181.x","volume":"95","author":"H Yagita","year":"2004","unstructured":"Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K (2004) TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95(10):777\u2013783","journal-title":"Cancer Sci"},{"issue":"4","key":"8048_CR18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coph.2004.02.006","volume":"4","author":"SK Kelley","year":"2004","unstructured":"Kelley SK, Ashkenazi A (2004) Targeting death receptors in cancer with Apo2L\/TRAIL. Curr Opin Pharmacol 4(4):333\u2013339","journal-title":"Curr Opin Pharmacol"},{"key":"8048_CR19","first-page":"65-79","volume":"67","author":"NB Liabakk","year":"2004","unstructured":"Liabakk NB, Espevik T (2004) Monoclonal antibodies against TRAIL. Vitam Horm 67:65\u201379","journal-title":"Vitam Horm"},{"issue":"3","key":"8048_CR20","first-page":"734","volume":"59","author":"MM Keane","year":"1999","unstructured":"Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59(3):734\u2013741","journal-title":"Cancer Res"},{"issue":"13","key":"8048_CR21","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.onc.1206290","volume":"22","author":"T Ohtsuka","year":"2003","unstructured":"Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T (2003) Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK\/p38 and mitochondrial death pathway. Oncogene 22(13):2034\u20132044","journal-title":"Oncogene"},{"issue":"12","key":"8048_CR22","first-page":"4537","volume":"9","author":"J An","year":"2003","unstructured":"An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB (2003) Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 9(12):4537\u20134545","journal-title":"Clin Cancer Res"},{"issue":"14","key":"8048_CR23","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/sj.onc.1207351","volume":"23","author":"Q He","year":"2004","unstructured":"He Q, Huang Y, Sheikh MS (2004) Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L\/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 23(14):2554\u20132558","journal-title":"Oncogene"},{"issue":"32","key":"8048_CR24","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1038\/sj.onc.1206656","volume":"22","author":"TR Johnson","year":"2003","unstructured":"Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, et\u00a0al (2003) The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22(32):4953\u20134963","journal-title":"Oncogene"},{"issue":"1","key":"8048_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2002-09-2975","volume":"102","author":"TJ Sayers","year":"2003","unstructured":"Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, et\u00a0al (2003) The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102(1):303\u2013310","journal-title":"Blood"},{"issue":"1","key":"8048_CR26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1128\/MCB.20.1.205-212.2000","volume":"20","author":"SB Gibson","year":"2000","unstructured":"Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL (2000) Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 20(1):205\u2013212","journal-title":"Mol Cell Biol"},{"issue":"51","key":"8048_CR27","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.1038\/sj.onc.1207004","volume":"22","author":"JB Johnston","year":"2003","unstructured":"Johnston JB, Kabore AF, Strutinsky J, Hu X, Paul JT, Kropp DM, et\u00a0al (2003) Role of the TRAIL\/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 22(51):8356\u20138369","journal-title":"Oncogene"},{"issue":"4","key":"8048_CR28","first-page":"847","volume":"60","author":"M Nagane","year":"2000","unstructured":"Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ (2000) Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60(4):847\u2013853","journal-title":"Cancer Res"},{"issue":"8","key":"8048_CR29","first-page":"1593","volume":"58","author":"MS Sheikh","year":"1998","unstructured":"Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, et\u00a0al (1998) p53-dependent and -independent regulation of the death receptor KILLER\/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 58(8):1593\u20131598","journal-title":"Cancer Res"},{"issue":"47","key":"8048_CR30","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1038\/sj.onc.1203025","volume":"18","author":"GS Wu","year":"1999","unstructured":"Wu GS, Burns TF, McDonald ER 3rd, Meng RD, Kao G, Muschel R, et\u00a0al (1999) Induction of the TRAIL receptor KILLER\/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene 18(47):6411\u20136418","journal-title":"Oncogene"},{"issue":"53","key":"8048_CR31","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1038\/sj.onc.1207232","volume":"22","author":"S Wang","year":"2003","unstructured":"Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22(53):8628\u20138633","journal-title":"Oncogene"},{"key":"8048_CR32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0083-6729(04)67011-7","volume":"67","author":"W Roth","year":"2004","unstructured":"Roth W, Reed JC (2004) FLIP protein and TRAIL-induced apoptosis. Vitam Horm 67:189\u2013206.","journal-title":"Vitam Horm"},{"key":"8048_CR33","doi-asserted-by":"crossref","unstructured":"Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, et\u00a0al (2002) Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 193\u2013213","DOI":"10.1182\/asheducation-2002.1.193"},{"issue":"9","key":"8048_CR34","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/sj.leu.2402201","volume":"15","author":"JB Almond","year":"2001","unstructured":"Almond JB, Snowden RT, Hunter A, Dinsdale D, Cain K, Cohen GM (2001) Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukemia 15(9):1388\u20131397","journal-title":"Leukemia"},{"issue":"11","key":"8048_CR35","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1182\/blood.V92.11.4220","volume":"92","author":"J Chandra","year":"1998","unstructured":"Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, et\u00a0al (1998) Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92(11):4220\u20134229","journal-title":"Blood"},{"issue":"8","key":"8048_CR36","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.leukres.2003.12.010","volume":"28","author":"TW Kelley","year":"2004","unstructured":"Kelley TW, Alkan S, Srkalovic G, Hsi ED (2004) Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res 28(8):845\u2013850","journal-title":"Leuk Res"},{"issue":"12","key":"8048_CR37","first-page":"4570","volume":"9","author":"JC Pahler","year":"2003","unstructured":"Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, et\u00a0al (2003) Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 9(12):4570\u20134577","journal-title":"Clin Cancer Res"},{"issue":"11","key":"8048_CR38","first-page":"1875","volume":"9","author":"A Begleiter","year":"1995","unstructured":"Begleiter A, Verburg L, Ashique A, Lee K, Israels LG, Mowat MR, et\u00a0al (1995) Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 9(11):1875\u20131881","journal-title":"Leukemia"},{"issue":"12","key":"8048_CR39","first-page":"1959","volume":"10","author":"A Begleiter","year":"1996","unstructured":"Begleiter A, Wang H, Verburg L, Lee K, Israels LG, Mowat MR, et\u00a0al (1996) In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia. Leukemia 10(12):1959\u20131965","journal-title":"Leukemia"},{"issue":"18","key":"8048_CR40","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1158\/0008-5472.CAN-04-1734","volume":"64","author":"S Wang","year":"2004","unstructured":"Wang S, El-Deiry WS (2004) Inducible silencing of KILLER\/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 64(18):6666\u20136672","journal-title":"Cancer Res"},{"issue":"3","key":"8048_CR41","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0301-472X(02)01076-7","volume":"31","author":"C Bogner","year":"2003","unstructured":"Bogner C, Schneller F, Hipp S, Ringshausen I, Peschel C, Decker T (2003) Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: Involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways. Exp Hematol 31(3):218\u2013225","journal-title":"Exp Hematol"},{"issue":"2B","key":"8048_CR42","first-page":"1213","volume":"23","author":"G Jonsson","year":"2003","unstructured":"Jonsson G, Paulie S, Grandien A (2003) High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. Anticancer Res 23(2B):1213\u20131218","journal-title":"Anticancer Res"},{"issue":"1","key":"8048_CR43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1006\/bbrc.1999.1641","volume":"265","author":"H Yamada","year":"1999","unstructured":"Yamada H, Tada-Oikawa S, Uchida A, Kawanishi S (1999) TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells. Biochem Biophys Res Commun 265(1):130\u2013133","journal-title":"Biochem Biophys Res Commun"},{"issue":"25","key":"8048_CR44","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1038\/sj.onc.1206520","volume":"22","author":"H Ehrhardt","year":"2003","unstructured":"Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I (2003) TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22(25):3842\u20133852","journal-title":"Oncogene"},{"issue":"3","key":"8048_CR45","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/sj.cdd.4400801","volume":"8","author":"AP MacLaren","year":"2001","unstructured":"MacLaren AP, Chapman RS, Wyllie AH, Watson CJ (2001) p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 8(3):210\u2013218","journal-title":"Cell Death Differ"},{"issue":"3","key":"8048_CR46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.neulet.2003.10.048","volume":"354","author":"K Nakaso","year":"2004","unstructured":"Nakaso K, Yoshimoto Y, Yano H, Takeshima T, Nakashima K (2004) p53-mediated mitochondrial dysfunction by proteasome inhibition in dopaminergic SH-SY5Y cells. Neurosci Lett 354(3):213\u2013216","journal-title":"Neurosci Lett"},{"issue":"46","key":"8048_CR47","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1038\/sj.onc.1206863","volume":"22","author":"Y Dai","year":"2003","unstructured":"Dai Y, Rahmani M, Grant S (2003) Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK\/JNK- and NF-kappaB-dependent process. Oncogene 22(46):7108\u20137122","journal-title":"Oncogene"},{"issue":"7","key":"8048_CR48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/bjc.1998.183","volume":"77","author":"J Delic","year":"1998","unstructured":"Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL, et\u00a0al (1998) The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 77(7):1103\u20131107","journal-title":"Br J Cancer"},{"issue":"3","key":"8048_CR49","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1365-2141.1999.01388.x","volume":"105","author":"P Masdehors","year":"1999","unstructured":"Masdehors P, Omura S, Merle-Beral H, Mentz F, Cosset JM, Dumont J, et\u00a0al (1999) Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 105(3):752\u2013757","journal-title":"Br J Haematol"},{"issue":"5","key":"8048_CR50","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1020031023947","volume":"7","author":"S Shetty","year":"2002","unstructured":"Shetty S, Gladden JB, Henson ES, Hu X, Villanueva J, Haney N, et\u00a0al (2002) Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. Apoptosis 7(5):413\u2013420","journal-title":"Apoptosis"},{"issue":"12","key":"8048_CR51","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1128\/MCB.21.12.3964-3973.2001","volume":"21","author":"S Kreuz","year":"2001","unstructured":"Kreuz S, Siegmund D, Scheurich P, Wajant H (2001) NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 21(12):3964\u20133973","journal-title":"Mol Cell Biol"},{"issue":"12","key":"8048_CR52","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/sj.leu.2402287","volume":"15","author":"A Olsson","year":"2001","unstructured":"Olsson A, Diaz T, Aguilar-Santelises M, Osterborg A, Celsing F, Jondal M, et\u00a0al (2001) Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 15(12):1868\u20131877","journal-title":"Leukemia"},{"issue":"2","key":"8048_CR53","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/00007890-200107270-00005","volume":"72","author":"H Luo","year":"2001","unstructured":"Luo H, Wu Y, Qi S, Wan X, Chen H, Wu J (2001) A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 72(2):196\u2013202","journal-title":"Transplantation"},{"issue":"21","key":"8048_CR54","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1073\/pnas.0401563101","volume":"101","author":"K Sun","year":"2004","unstructured":"Sun K, Welniak LA, Panoskaltsis-Mortari A, O\u2019Shaughnessy MJ, Liu H, Barao I, et\u00a0al (2004) Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 101(21):8120\u20138125","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"44","key":"8048_CR55","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1038\/sj.onc.1205853","volume":"21","author":"M MacFarlane","year":"2002","unstructured":"MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, et\u00a0al (2002) Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21(44):6809\u20136818","journal-title":"Oncogene"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-006-8048-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10495-006-8048-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-006-8048-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T21:15:27Z","timestamp":1586898927000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10495-006-8048-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,11]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["8048"],"URL":"https:\/\/doi.org\/10.1007\/s10495-006-8048-9","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,11]]}}}